AIIMS Delhi Gives 30-year-old Man 1st Dose of Bharat Biotech's Potential COVID-19 Vaccine

AIIMS Delhi administered its first dose of Bharat Biotech's 'Covaxin' to a 30-year-old man on Friday. The development comes days after the ethics committee gave approval to AIIMS Delhi to begin the human trials of the potential Covid-19 vaccine.

The second dose will be given to the subject after a period of two weeks in which he will be monitored, states a report by the News. AIIMS, Delhi is one of the 12 sites selected by ICMR for conducting Phase I and II randomised, double-blind and placebo-controlled clinical trials of Covaxin, the report adds.

Dr Sanjay Rai, Principal Investigator Covid-19 vaccine trial at AIIMS told IE that the first dose of 0.5 ml of the intramuscular vaccine was given to the subject on Friday, who was observed for two hours.

Rai said that a diary had also been given to him to constantly monitor his condition, and that the team would coordinate with him daily for a week to understand if he



encounters any medical issues.

The phase I and II clinical preliminaries of the immunization for SARS-CoV-2 by Bharat Biotech have been endorsed by the Indian medication controller after pre-clinical examinations exhibited wellbeing and resistant reaction. 

The organization has built up the antibody in a joint effort with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). 

The phase I of the antibody would see it being tried of 375 volunteers and 100 of them would be from AIIMS. A sum of 750 volunteers from each of the 12 locales would be remembered for the subsequent stage. AIIMS, Delhi has now gotten more than 3,500 uses of the individuals who need to take part in the preliminaries.

Dr Rai said 20 volunteers had been shortlisted to participated in the trial, after several tests were conducted on them, and that the results were awaited, stated the report.